Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Theravance Biopharma (TBPH) Invested Capital (2016 - 2025)

Theravance Biopharma (TBPH) has disclosed Invested Capital for 13 consecutive years, with $232.7 million as the latest value for Q3 2025.

  • On a quarterly basis, Invested Capital rose 25.33% to $232.7 million in Q3 2025 year-over-year; TTM through Sep 2025 was $232.7 million, a 25.33% increase, with the full-year FY2024 number at $175.5 million, changed N/A from a year prior.
  • Invested Capital was $232.7 million for Q3 2025 at Theravance Biopharma, up from $224.8 million in the prior quarter.
  • In the past five years, Invested Capital ranged from a high of $480.6 million in Q3 2022 to a low of -$361.6 million in Q1 2021.
  • A 5-year average of $90.8 million and a median of $193.7 million in 2024 define the central range for Invested Capital.
  • Peak YoY movement for Invested Capital: tumbled 128.93% in 2021, then soared 254.5% in 2022.
  • Theravance Biopharma's Invested Capital stood at -$311.1 million in 2021, then surged by 242.03% to $441.8 million in 2022, then plummeted by 44.29% to $246.1 million in 2023, then dropped by 28.68% to $175.5 million in 2024, then soared by 32.55% to $232.7 million in 2025.
  • Per Business Quant, the three most recent readings for TBPH's Invested Capital are $232.7 million (Q3 2025), $224.8 million (Q2 2025), and $166.0 million (Q1 2025).